A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Oral Oncology

• Publication date

  2013-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.oraloncology.2012.11.008PMID 23312237
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors

  2012cited by this paper
• Comparison of the NCI-CTCAE version 4.0 and version 3.0 in assessing chemoradiation-induced oral mucositis for locally advanced nasopharyngeal carcinoma.

  2012cited by this paper
• A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE)

  2011cited by this paper
• Clinical presentation and management of mTOR inhibitor-associated stomatitis.

  2011cited by this paper
• Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer

  2011cited by this paper
• Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues.

  2011cited by this paper
• Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies

  2011cited by this paper
• Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer.

  2010cited by this paper
• Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer

  2010cited by this paper
• Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies

  2010cited by this paper
• Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.

  2010cited by this paper
• Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer

  2010cited by this paper
• Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors

  2010cited by this paper
• Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.

  2010cited by this paper
• Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel.

  2010cited by this paper
• A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors.

  2010cited by this paper
• Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.

  2010cited by this paper
• Daily Oral Everolimus Activity in Patients with Metastatic Pancreatic Neuroendocrine Tumors after Failure of Cytotoxic Chemotherapy: A Phase II Trial

  2010cited by this paper
• Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.

  2009cited by this paper
• Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

  2009cited by this paper
• Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours

  2009cited by this paper
• Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.

  2009cited by this paper
• The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents

  2009cited by this paper
• A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

  2009cited by this paper
• Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma.

  2009cited by this paper
• Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.

  2009cited by this paper
• Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients

  2009cited by this paper
• Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

  2009cited by this paper
• Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy

  2009cited by this paper
• A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies

  2009cited by this paper
• Deforolimus (AP23573) a novel mTOR inhibitor in clinical development

  2008cited by this paper
• A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies

  2008cited by this paper
• Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

  2008influential reference
• mTOR pathway and mTOR inhibitors as agents for cancer therapy.

  2008cited by this paper
• Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.

  2008influential reference
• The potential role of mTOR inhibitors in non-small cell lung cancer.

  2008cited by this paper
• Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.

  2008cited by this paper
• Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

  2008cited by this paper
• Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall‐cell lung cancer

  2007cited by this paper
• Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

  2007cited by this paper
• Phase I study of everolimus in pediatric patients with refractory solid tumors.

  2007cited by this paper
• Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.

  2007cited by this paper
• Current development of mTOR inhibitors as anticancer agents

  2006cited by this paper
• Mucosal disease series. Number VI. Recurrent aphthous stomatitis.

  2006cited by this paper
• Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies

  2006cited by this paper
• Number VI Recurrent aphthous stomatitis

  2006cited by this paper
• A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer

  2006cited by this paper
• Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.

  2005cited by this paper
• Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.

  2005cited by this paper
• Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.

  2005cited by this paper
• Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs

  2004cited by this paper
• Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.

  2004influential reference
• CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium.

  2004cited by this paper
• The NCI Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 is the new standard for oncology clinical trials

  2004cited by this paper
• Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.

  2004cited by this paper
• Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors.

  2003influential reference
• Recurrent aphthous stomatitis.

  1998cited by this paper

• Safety of Sirolimus in the Treatment of Vascular Anomalies in Asian Children

  2025cites this paper
• β-Sitosterol modulates osteogenic and adipogenic balance in BMSCs to suppress osteoporosis via regulating mTOR-IMP1-Adipoq axis.

  2025cites this paper
• Current and Emerging Therapies for Targeting the ERK1/2 & PI3K Pathways in Cancer

  2025cites this paper
• Salivary and Serum Cytokine Concentrations in Kidney Transplantation: A Prospective Study.

  2025cites this paper
• Maintenance Immunosuppression in Kidney Transplantation: A Review of the Current Status and Future Directions

  2025cites this paper
• Oral mucosal toxicities in oncology

  2025influential citation
• Management of gastrointestinal side effects of cancer pharmacotherapy: Part 1: Diarrhoea, constipation, mucositis and anorexia.

  2025cites this paper
• Navigating Stomatologic Complications Secondary to Antineoplastic Agents—A Comprehensive Review

  2025cites this paper
• Vascular malformations: from genetics to therapeutics

  2025cites this paper
• Targeting the EGFR pathway: An alternative strategy for the treatment of tuberous sclerosis complex?

  2024cites this paper
• Disproportionality Analysis of Stomatitis Associated with Anticancer Drugs Using the Japanese Adverse Drug Event Report Database

  2024cites this paper
• Emerging pharmacotherapy trends in preventing and managing oral mucositis induced by chemoradiotherapy and targeted agents

  2024influential citation
• Fact-Finding Survey and Exploration of Preventive Drugs for Antineoplastic Drug-Induced Oral Mucositis Using the Japanese Adverse Drug Event Report Database

  2024cites this paper
• Toxicités des traitements anticancéreux sur la muqueuse buccale

  2023cites this paper
• Upregulation of the ESCRT pathway and multivesicular bodies accelerates degradation of proteins associated with neurodegeneration

  2023cites this paper
• Transcriptome Sequencing Reveals the Mechanism behind Chemically Induced Oral Mucositis in a 3D Cell Culture Model

  2023cites this paper
• Pathogenesis of Oral Toxicities Associated with Targeted Therapy and Immunotherapy

  2023cites this paper
• A New Hypothesis Describing the Pathogenesis of Oral Mucosal Injury Associated with the Mammalian Target of Rapamycin (mTOR) Inhibitors

  2023cites this paper
• Exploring and exploiting the host cell autophagy during Mycobacterium tuberculosis infection

  2023cites this paper
• Systemische Medikamenteneinnahme und ihr potenzieller Einfluss auf die orale Gesundheit

  2023cites this paper
• The present and the future of benzydamine: expert opinion paper

  2023cites this paper
• Oral Mucositis

  2022cites this paper
• J‐SUPPORT research policy for oral mucositis associated with cancer treatment

  2022cites this paper
• Phase I study of ribociclib and everolimus in children with newly diagnosed DIPG and high-grade glioma: A CONNECT pediatric neuro-oncology consortium report

  2022cites this paper
• Drug-Specific Orofacial Complications of Novel Anti-cancer Therapies

  2022cites this paper
• Amplification of human interneuron progenitors promotes brain tumors and neurological defects

  2022cites this paper
• Everolimus-Induced Oral Mucositis Can be Prevented by Hippophae Rhamnoides Extract in Rats

  2021cites this paper
• Miscellaneous Disorders with Oral Manifestations

  2021cites this paper
• The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies

  2021cites this paper
• Oral Complications of Nonsurgical Cancer Therapies

  2021cites this paper
• ESTOMATITIS ASOCIADA A INHIBIDORES mTOR: PUESTA AL DÍA EN LA VALORACIÓN, PREVENCIÓN Y MANEJO.

  2021cites this paper
• La atención y los cuidados a los supervivientes de cáncer en España: un reto pendiente de las políticas sanitarias

  2021influential citation
• Transzplantált betegek fogorvosi-szájsebészeti ellátásának alapelvei

  2020cites this paper
• Mammalian Target of Rapamycin (mTOR) Inhibitors Induce Stomatitis in Patients with Metastatic Breast Cancer (Review)

  2020cites this paper
• Dermatological Toxicities of Targeted Therapy

  2020cites this paper
• Genetics and oral health

  2020cites this paper
• Adverse Drug Events in the Oral Cavity.

  2020cites this paper
• Use of a natural multicomponent mouthwash plus oral hygiene vs oral hygiene alone to prevent everolimus-induced stomatitis: the STOP multicenter, randomized trial

  2020cites this paper
• Combination Therapies in Solid Tumour Oncology

  2020cites this paper
• Cerebral organoid model reveals excessive proliferation of human caudal late interneuron progenitors in Tuberous Sclerosis Complex

  2020cites this paper
• Complications digestives des traitements anticancéreux

  2020cites this paper
• Random Allocated Study of Wrapping Oblate for Prevention of Everolimus-associated Stomatitis in Patients With Metastatic Renal Cell Carcinoma

  2019cites this paper
• A review and guide to drug-associated oral adverse effects-Oral mucosal and lichenoid reactions. Part 2.

  2019cites this paper
• Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis

  2019cites this paper
• A single-arm, phase 2 study of steroid-containing mouthwash for the prevention of everolimus-associated stomatitis in multiple tumor types

  2019cites this paper
• Oral mucosal changes associated with primary diseases in other body systems.

  2019cites this paper
• OTT_A_195121 9669..9683

  2019cites this paper
• Management of mTOR inhibitors oral mucositis: current state of knowledge

  2019cites this paper
• Cytoprotective Agents to avoid Chemotherapy Induced Sideeffects on Normal Cells: A Review.

  2019cites this paper
• Fahreignung onkologischer Patienten

  2019cites this paper
• Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation

  2019cites this paper
• The coding and non-coding transcriptional landscape of subependymal giant cell astrocytomas

  2019cites this paper
• Stomatitis And Everolimus: A Review Of Current Literature On 8,201 Patients

  2019cites this paper
• Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors

  2019cites this paper
• Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside

  2019cites this paper
• Cutaneous Complications in Recipients of Lung Transplants: A Pictorial Review.

  2019cites this paper
• Oral Mucosal Injury Caused by Targeted Cancer Therapies.

  2019cites this paper
• Everolimus‐associated perianal ulcers in an eight‐month‐old heart transplant recipient

  2018cites this paper
• Breast cancer patients have increased risk of developing mTOR inhibitor-associated stomatitis.

  2018cites this paper
• Practical management of toxicities associated with targeted therapies for advanced gastroenteropancreatic neuroendocrine tumors

  2018cites this paper
• Prevention of Stomatitis

  2018cites this paper
• Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies

  2018cites this paper
• Stomatitis associated with mammalian target of rapamycin inhibition: A review of pathogenesis, prevention, treatment, and clinical implications for oral practice in metastatic breast cancer.

  2018cites this paper
• Chemical probes and drug leads from advances in synthetic planning and methodology

  2018cites this paper
• An Update on Drug-induced Oral Reactions.

  2018cites this paper
• Usefulness of Dexamethasone Ointment for Preventing Everolimus-induced Stomatitis

  2018cites this paper
• Complications digestives des traitements anticancéreux

  2018cites this paper
• Fahreignung onkologischer Patienten

  2017cites this paper
• Everolimus-related adverse events in neuroendocrine tumors and comparative considerations with breast and renal cancer: a critical overview

  2017cites this paper
• A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer

  2017cites this paper
• Glimpses of the near future: a new generation of mTOR inhibitors.

  2017cites this paper
• Bacterial Pneumonia in Patients with Cancer: Novel Risk Factors and Management.

  2017cites this paper
• Oral Complications of Nonsurgical Cancer Therapies.

  2017cites this paper
• Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors

  2017influential citation
• Fahreignung onkologischer Patienten

  2017cites this paper
• Oral Manifestations of Immunodeficiencies and Transplantation Medicine.

  2017cites this paper
• On the pathogenesis of mTOR inhibitor-associated stomatitis (mIAS)-studies using an organotypic model of the oral mucosa.

  2017cites this paper
• Prevention and treatment options for mTOR inhibitor-associated stomatitis

  2017cites this paper
• Fahreignung onkologischer Patienten

  2017cites this paper
• The Clinical Pharmacology and Toxicity Profile of Rapalogs

  2016influential citation
• Safety of mTOR inhibitors in breast cancer

  2016cites this paper
• Oral squamous cell carcinoma: Key clinical questions, biomarker discovery, and the role of proteomics.

  2016cites this paper
• Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice

  2016influential citation
• Prevention of allograft rejection in heart transplantation through concurrent gene silencing of TLR and Kinase signaling pathways

  2016cites this paper
• Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents

  2016cites this paper
• Safety, Efficacy, and Patient Acceptability of Everolimus in the Treatment of Breast Cancer

  2016cites this paper
• Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy

  2016cites this paper
• Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours.

  2016cites this paper
• The Impact of Cancer Treatments on Aging

  2016cites this paper
• Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours.

  2015cites this paper
• Pharmacogenomics for Oral Disease

  2015cites this paper
• Current management of mTOR inhibitor-associated stomatitis

  2015cites this paper
• Toxicités orales des thérapies ciblées anticancéreuses

  2015cites this paper
• Stomatitis Associated With Use of mTOR Inhibitors: Implications for Patients With Invasive Breast Cancer.

  2015cites this paper
• Adverse drug events in the oral cavity.

  2015cites this paper
• Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: A pooled analysis

  2015cites this paper
• Understanding Toxicities of Targeted Agents: Implications for Anti-tumor Activity and Management.

  2015cites this paper
• Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update.

  2015cites this paper
• Incidence and risk of rash to mTOR inhibitors in cancer patients – a meta-analysis of randomized controlled trials

  2015cites this paper
• Incidence and Risk of High-grade Stomatitis with mTOR Inhibitors in Cancer Patients

  2015influential citation